Trial Profile
A large scale clinical study of APN01 in the patients with COVID-19 infections
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 12 Jul 2021
Price :
$35
*
At a glance
- Drugs Alunacedase alfa (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 12 Jul 2021 New trial record
- 06 Jul 2021 According to an APEIRON Biologics AG media release, based on promising results of phase 2 study , APN01 was selected for a publicly funded, large-scale study in COVID-19 by the U.S. government which is scheduled to start in Q3 2021.